A Case of Multiple Tuberculosis Associated with Infliximab Therapy in Crohn's Disease.
- Author:
Hee Wook KIM
1
;
Sung Ill JANG
;
Bun KIM
;
Young Hoon YOUN
;
Min Kwang BYUN
;
Hyo Jin PARK
;
Sang In LEE
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. hypark21@yuhs.ac
- Publication Type:Case Report
- Keywords:
Infliximab;
Tuberculosis;
Tumor necrosis factor-alpha
- MeSH:
Antibodies, Monoclonal;
Crohn Disease;
Humans;
Latent Tuberculosis;
Mass Screening;
Tuberculosis;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Medicine
2012;83(3):337-341
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infliximab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been approved for the treatment of a variety of inflammatory illnesses, including Crohn's disease. However, infliximab can increase the risk of reactivation of latent tuberculosis (Tbc) infection by affecting host immune responses. Therefore, a screening test should be performed before the initiation of infliximab therapy, and patients with evidence of latent infection should be treated with prophylactic anti-Tbc therapy. Here, we report a case of multifocal disseminated tuberculosis after treatment with infliximab in a patient diagnosed with Crohn's disease who had no past history of Tbc and showed a negative screening test.
